Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...

Adding daratumumab to lenalidomide maintenance therapy after transplant in patients with multiple myeloma triples the minimal residual disease (MRD)–negative conversion rate to 50.5% vs 18.8% with ...

Lupin has received approval from the Food and Drug Administration for lenalidomide capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg, which are the generic of Bristol-Myers Squibb's Revlimid. The ...

Rituximab and lenalidomide combination therapy shows promise for relapsed/refractory indolent non-Hodgkin lymphoma, with high response and remission rates. The AUGMENT trial demonstrated favorable ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic ...

Lenalidomide maintenance therapy in patients with MM reduces antibody production but preserves T-cell responses post-vaccination. mRNA vaccines enhance CD4+ and CD8+ responses, providing protective ...

TORONTO -- A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data. The ...

The federal government has approved the multiple myeloma drug lenalidomide for a new group of patients, and Dr. Philip McCarthy of Roswell Park Cancer Institute was at the heart of the work.

The recommended starting dosage of lenalidomide for the treatment of MM is 25 mg/day p.o. on days 1-21 of a 28-day cycle. On the basis of the trials previously presented, the recommended dosage of ...